Avalon GloboCare Enters Agreement to Repurchase 100% of Outstanding Warrants
October 21, 2019 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced plans to repurchase...
Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Cell Malignancies
September 19, 2019 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has initiated its...
Avalon GloboCare Announces $20 Million Credit Facility Provided by Company Chairman
September 03, 2019 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced it...
Avalon GloboCare and GE Healthcare Announce Strategic Partnership to Accelerate Standardized Automation and Bio-production for Cellular Medicines
July 22, 2019 16:30 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced that...
Avalon GloboCare Provides Updates on its Lead Clinical Programs in CAR-T Therapy and Exosome-Based Regenerative Therapeutics
July 15, 2019 08:00 ET
|
Avalon GloboCare Corp.
CD19 CAR-T candidate, AVA-001, has entered first-in-human clinical study for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in July 2019Next-generation,...
Avalon GloboCare Appoints Dr. Yen-Michael Sheng Hsu, Founding Director of cGMP Cellular Therapy Facility at Weill Cornell Medicine, to its Scientific and Clinical Advisory Board
June 26, 2019 08:30 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., June 26, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company has...
Avalon GloboCare Partners with MIT to Develop Innovative AI-Enhanced Protein Design Technology in Cellular Therapy
May 21, 2019 09:00 ET
|
Avalon GloboCare Corp.
MIT Professors Robert S. Langer and Shuguang Zhang as Co-Principal Investigators Plan to Utilize Innovative “QTY Code" Modified Proteins as Novel Therapeutic Targets FREEHOLD, N.J., May 21, 2019 ...
Avalon GloboCare Announces Filing of Provisional Patent Applications for AVA-101, a Novel Transposon-Based, Multi-Targeted CAR-T Therapy
February 26, 2019 08:00 ET
|
Avalon GloboCare Corp.
AVA-101 designed to enhance efficacy and overcome safety challenges of current CAR-T immune-oncology therapeutics AVA-101 represents a first-in-class transposon-based Chimeric Antigen Receptor (CAR)...
Avalon GloboCare Announces Breakthrough in Identifying Human Angiogenic Exosomes/Extracellular Vesicles (EV) Derived from Endothelial Cells
February 11, 2019 08:30 ET
|
Avalon GloboCare Corp.
Angiogenic exosomes containing angiogenic factors developed to promote new blood vessel formation and tissue regeneration upon release from exosomes. Results from Avalon’s co-development program with...
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the “Status of Cellular Therapy in the Asia Pacific Rim” Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASBMT and CIBMTR Tandem Meeting 2019
February 04, 2019 08:15 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (NASDAQ listed Avalon GloboCare AVCO), a leading global developer of cell-based technologies and therapeutics,...